Abstract
Background: Primary hyperparathyroidism (PHPT) is associated with metabolic disorders, endothelial dysfunction, and increased cardiovascular risk. Soluble endoglin (sENG), an endothelium-derived biomarker, is a potential indicator of TGF-β-related vascular stress. This study aimed to compare serum sENG levels between patients with asymptomatic PHPT and healthy controls and to evaluate the association between sENG and metabolic parameters.
Methods: This cross-sectional study included 42 patients with biochemically confirmed asymptomatic PHPT and 39 age- and sex-matched healthy controls. Serum sENG levels and metabolic parameters were compared between groups. Welch t-test, chi-square test, correlation, and regression analyses were used to evaluate potential associations.
Results: Serum sENG levels were similar in the PHPT and control groups (1.40±1.13 vs. 1.46±1.31 ng/mL, p=0.83). In the PHPT group, weak-to-moderate positive trends were observed between sENG and body mass index, fasting glucose, insulin, and HOMA-IR, whereas these trends were less pronounced in controls. In linear regression analysis, body weight was identified as an independent determinant of sENG in the PHPT group (p=0.047). In two-way ANOVA, no significant main or interaction effects were detected; however, borderline interaction trends were observed for glucose and body mass index.
Conclusion: Serum sENG levels did not differ significantly between asymptomatic PHPT and control groups. However, the observed trends between sENG and metabolic parameters in patients with PHPT suggest that sENG may reflect early interactions between metabolic burden and endothelial response even in the absence of a marked biochemical increase. Larger prospective studies may clarify the clinical and pathophysiological significance of sENG in PHPT.
Keywords
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.